Currently Viewing:
Currently Reading
What We're Reading: Awaiting Alzheimer's Drug Clinical Trial Results
October 13, 2016 – AJMC Staff
What We're Reading: Limiting Use of Fentanyl, the Drug Fueling the Opioid Epidemic
October 12, 2016 – AJMC Staff
What We're Reading: Tying Medical Organization Recommendations to Insurance Coverage
October 11, 2016 – AJMC Staff
COST: A New Tool to Measure Financial Toxicity as a PRO
October 10, 2016 – Surabhi Dangi-Garimella, PhD
Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC
October 10, 2016 – Surabhi Dangi-Garimella, PhD
Jakafi Named Recommended Treatment for Myelofibrosis in NCCN Guideline
October 09, 2016 – Laura Joszt
Payment Tied to Patient Experience Improvement Benefits Hospitals Serving Minority Patients
October 08, 2016 – Jackie Syrop
5 Key Takeaways From AMCP Nexus 2016
October 07, 2016 – Laura Joszt
Tamoxifen and AI Can Reduce Long-Term Risk of Contralateral Breast Cancer
October 07, 2016 – Surabhi Dangi-Garimella, PhD

What We're Reading: Awaiting Alzheimer's Drug Clinical Trial Results

AJMC Staff
What we’re reading, October 13, 2016: researchers, Alzheimer’s patients, and their families anxiously await the results of a clinical trial that could help slow the disease’s progress; many breast cancers detected by mammograms are overtreated even though they likely would not be fatal on their own; stock prices fall for Humana and Cigna as CMS says a minority of their patients are in plans rated 4 stars or higher.
Clinical trial results for a drug to treat Alzheimer’s disease should be released in the coming month, leaving researchers, patients, and their families cautiously optimistic in the meantime. Solanezumab, which is being tested by Eli Lilly, is an injected antibody that could potentially clear the plaques that accumulate in the brains of patients with Alzheimer’s disease. However, researchers worry that the drug could join the 99% of experimental treatments for the disease that have failed in clinical trials, which would further crush hope for those affected.

More than half of women diagnosed with breast cancer after a mammogram received treatment they didn’t actually need, subjecting them to unnecessary anxiety, treatments, and costs. A study in the New England Journal of Medicine found that most abnormalities detected by mammograms would likely never become deadly tumors if left untreated. Researchers now say that the mammogram's status as a life-saving prevention measure may be overblown, and more effective treatments, not screening measures, are the reason breast cancer survival rates have improved.

Humana and Cigna both suffered drops in stock prices after CMS released discouraging star ratings. The percentage of Medicare Advantage patients in Humana plans that rated 4 stars or higher fell to 37%, down from 78% last year; only 20% of Cigna’s patients are in 4-star or higher plans. In contrast, 91% of Aetna members are in 4-star plans. 

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up